Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.

Yu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JPW, DeIuliis G, Ahangari F, Woolard T, Aurelien N, Arrojo E Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N.

Nat Med. 2018 Jan;24(1):39-49. doi: 10.1038/nm.4447. Epub 2017 Dec 4.

PMID:
29200204
2.

Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy.

Meinig JM, Ferrara SJ, Banerji T, Banerji T, Sanford-Crane HS, Bourdette D, Scanlan TS.

ACS Chem Neurosci. 2017 Nov 15;8(11):2468-2476. doi: 10.1021/acschemneuro.7b00239. Epub 2017 Aug 18.

PMID:
28756656
3.

Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.

Ma H, Yang F, Butler MR, Belcher J, Redmond TM, Placzek AT, Scanlan TS, Ding XQ.

FASEB J. 2017 Aug;31(8):3425-3438. doi: 10.1096/fj.201601166RR. Epub 2017 Apr 20.

PMID:
28428265
4.

Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.

Ferrara SJ, Meinig JM, Placzek AT, Banerji T, McTigue P, Hartley MD, Sanford-Crane HS, Banerji T, Bourdette D, Scanlan TS.

Bioorg Med Chem. 2017 May 15;25(10):2743-2753. doi: 10.1016/j.bmc.2017.03.047. Epub 2017 Mar 23.

PMID:
28385597
5.

A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy.

Hartley MD, Kirkemo LL, Banerji T, Scanlan TS.

Endocrinology. 2017 May 1;158(5):1328-1338. doi: 10.1210/en.2016-1842.

PMID:
28200172
6.

Sobetirome prodrug esters with enhanced blood-brain barrier permeability.

Placzek AT, Ferrara SJ, Hartley MD, Sanford-Crane HS, Meinig JM, Scanlan TS.

Bioorg Med Chem. 2016 Nov 15;24(22):5842-5854. doi: 10.1016/j.bmc.2016.09.038. Epub 2016 Sep 16.

7.

Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy.

Fernando R, Placzek E, Reese EA, Placzek AT, Schwartz S, Trierweiler A, Niziol LM, Raychaudhuri N, Atkins S, Scanlan TS, Smith TJ.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):776-785. doi: 10.1210/jc.2016-2762.

PMID:
27768856
8.

Increasing Thyromimetic Potency through Halogen Substitution.

Devereaux J, Ferrara SJ, Banerji T, Placzek AT, Scanlan TS.

ChemMedChem. 2016 Oct 12. doi: 10.1002/cmdc.201600408. [Epub ahead of print]

PMID:
27731931
9.

Implication of thyroid hormone signaling in neural crest cells migration: Evidence from thyroid hormone receptor beta knockdown and NH3 antagonist studies.

Bronchain OJ, Chesneau A, Monsoro-Burq AH, Jolivet P, Paillard E, Scanlan TS, Demeneix BA, Sachs LM, Pollet N.

Mol Cell Endocrinol. 2017 Jan 5;439:233-246. doi: 10.1016/j.mce.2016.09.007. Epub 2016 Sep 10.

PMID:
27619407
10.

New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3.

Placzek AT, Scanlan TS.

Tetrahedron. 2015 Sep 2;71(35):5946-5951. doi: 10.1016/j.tet.2015.05.049. Epub 2015 May 20.

11.

Intrinsic expression of a multiexon type 3 deiodinase gene controls zebrafish embryo size.

Guo C, Chen X, Song H, Maynard MA, Zhou Y, Lobanov AV, Gladyshev VN, Ganis JJ, Wiley D, Jugo RH, Lee NY, Castroneves LA, Zon LI, Scanlan TS, Feldman HA, Huang SA.

Endocrinology. 2014 Oct;155(10):4069-80. doi: 10.1210/en.2013-2029. Epub 2014 Jul 8.

12.

Effects of acute microinjections of the thyroid hormone derivative 3-iodothyronamine to the preoptic region of adult male rats on sleep, thermoregulation and motor activity.

James TD, Moffett SX, Scanlan TS, Martin JV.

Horm Behav. 2013 Jun;64(1):81-8. doi: 10.1016/j.yhbeh.2013.05.004. Epub 2013 May 20.

13.

NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment.

Haviland JA, Reiland H, Butz DE, Tonelli M, Porter WP, Zucchi R, Scanlan TS, Chiellini G, Assadi-Porter FM.

Obesity (Silver Spring). 2013 Dec;21(12):2538-44. doi: 10.1002/oby.20391. Epub 2013 May 29.

14.

THE SYNTHESIS OF 13C9-15N-LABELED 3,5-DIIODOTHYRONINE AND THYROXINE.

Hackenmueller SA, Scanlan TS.

Synth Commun. 2013;43(10):1439-1446. doi: 10.1080/00397911.2011.639005. Epub 2012 Jun 5.

15.

Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4.

Hackenmueller SA, Marchini M, Saba A, Zucchi R, Scanlan TS.

Endocrinology. 2012 Nov;153(11):5659-67. doi: 10.1210/en.2012-1254. Epub 2012 Sep 4.

16.

Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.

Goldberg IJ, Huang LS, Huggins LA, Yu S, Nagareddy PR, Scanlan TS, Ehrenkranz JR.

Endocrinology. 2012 Nov;153(11):5143-9. doi: 10.1210/en.2012-1572. Epub 2012 Sep 4.

17.

Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography-tandem mass spectrometry.

Hackenmueller SA, Scanlan TS.

J Chromatogr A. 2012 Sep 21;1256:89-97. doi: 10.1016/j.chroma.2012.07.052. Epub 2012 Jul 25.

18.

ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.

Roy G, Placzek E, Scanlan TS.

J Biol Chem. 2012 Jan 13;287(3):1790-800. doi: 10.1074/jbc.M111.275552. Epub 2011 Nov 28.

19.

Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis?

Hoefig CS, Renko K, Piehl S, Scanlan TS, Bertoldi M, Opladen T, Hoffmann GF, Klein J, Blankenstein O, Schweizer U, Köhrle J.

Mol Cell Endocrinol. 2012 Feb 26;349(2):195-201. doi: 10.1016/j.mce.2011.10.024. Epub 2011 Oct 28.

PMID:
22061622
20.

Detection of 3-iodothyronamine in human patients: a preliminary study.

Galli E, Marchini M, Saba A, Berti S, Tonacchera M, Vitti P, Scanlan TS, Iervasi G, Zucchi R.

J Clin Endocrinol Metab. 2012 Jan;97(1):E69-74. doi: 10.1210/jc.2011-1115. Epub 2011 Oct 26.

PMID:
22031514
21.

Cardioprotective effect of 3-iodothyronamine in perfused rat heart subjected to ischemia and reperfusion.

Frascarelli S, Ghelardoni S, Chiellini G, Galli E, Ronca F, Scanlan TS, Zucchi R.

Cardiovasc Drugs Ther. 2011 Aug;25(4):307-13. doi: 10.1007/s10557-011-6320-x.

PMID:
21786214
22.

Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity.

Venditti P, Napolitano G, Di Stefano L, Chiellini G, Zucchi R, Scanlan TS, Di Meo S.

Mol Cell Endocrinol. 2011 Jul 20;341(1-2):55-62. doi: 10.1016/j.mce.2011.05.013. Epub 2011 Jun 1.

23.

Endogenous 3-iodothyronamine (T1AM): more than we bargained for.

Scanlan TS.

J Clin Endocrinol Metab. 2011 Jun;96(6):1674-6. doi: 10.1210/jc.2011-0688. No abstract available.

PMID:
21602461
24.

3-Iodothyronamine metabolism and functional effects in FRTL5 thyroid cells.

Agretti P, De Marco G, Russo L, Saba A, Raffaelli A, Marchini M, Chiellini G, Grasso L, Pinchera A, Vitti P, Scanlan TS, Zucchi R, Tonacchera M.

J Mol Endocrinol. 2011 Jul 12;47(1):23-32. doi: 10.1530/JME-10-0168. Print 2011 Aug.

PMID:
21511808
25.

In vivo activity of the thyroid hormone receptor beta- and α-selective agonists GC-24 and CO23 on rat liver, heart, and brain.

Grijota-Martínez C, Samarut E, Scanlan TS, Morte B, Bernal J.

Endocrinology. 2011 Mar;152(3):1136-42. doi: 10.1210/en.2010-0813. Epub 2011 Jan 14.

26.

Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange.

Figueira AC, Saidemberg DM, Souza PC, Martínez L, Scanlan TS, Baxter JD, Skaf MS, Palma MS, Webb P, Polikarpov I.

Mol Endocrinol. 2011 Jan;25(1):15-31. doi: 10.1210/me.2010-0202. Epub 2010 Nov 24.

27.

Thyronamines--past, present, and future.

Piehl S, Hoefig CS, Scanlan TS, Köhrle J.

Endocr Rev. 2011 Feb;32(1):64-80. doi: 10.1210/er.2009-0040. Epub 2010 Sep 29. Review.

PMID:
20880963
28.

Tissue distribution and cardiac metabolism of 3-iodothyronamine.

Saba A, Chiellini G, Frascarelli S, Marchini M, Ghelardoni S, Raffaelli A, Tonacchera M, Vitti P, Scanlan TS, Zucchi R.

Endocrinology. 2010 Oct;151(10):5063-73. doi: 10.1210/en.2010-0491. Epub 2010 Aug 25.

PMID:
20739399
29.

The T3 receptor beta1 isoform regulates UCP1 and D2 deiodinase in rat brown adipocytes.

Martinez de Mena R, Scanlan TS, Obregon MJ.

Endocrinology. 2010 Oct;151(10):5074-83. doi: 10.1210/en.2010-0533. Epub 2010 Aug 18.

PMID:
20719854
30.

Contribution of a membrane estrogen receptor to the estrogenic regulation of body temperature and energy homeostasis.

Roepke TA, Bosch MA, Rick EA, Lee B, Wagner EJ, Seidlova-Wuttke D, Wuttke W, Scanlan TS, Rønnekleiv OK, Kelly MJ.

Endocrinology. 2010 Oct;151(10):4926-37. doi: 10.1210/en.2010-0573. Epub 2010 Aug 4.

31.

3-Iodothyronamine (T(1)AM): a new chapter of thyroid hormone endocrinology?

Ianculescu AG, Scanlan TS.

Mol Biosyst. 2010 Aug;6(8):1338-44. doi: 10.1039/b926583j. Epub 2010 Mar 4. Review.

PMID:
20623079
32.

3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator.

Gompf HS, Greenberg JH, Aston-Jones G, Ianculescu AG, Scanlan TS, Dratman MB.

Brain Res. 2010 Sep 10;1351:130-40. doi: 10.1016/j.brainres.2010.06.067. Epub 2010 Jul 23.

33.

Polybrominated diphenyl ethers induce developmental neurotoxicity in a human in vitro model: evidence for endocrine disruption.

Schreiber T, Gassmann K, Götz C, Hübenthal U, Moors M, Krause G, Merk HF, Nguyen NH, Scanlan TS, Abel J, Rose CR, Fritsche E.

Environ Health Perspect. 2010 Apr;118(4):572-8. doi: 10.1289/ehp.0901435.

34.

The TRbeta-selective agonist, GC-1, stimulates mitochondrial oxidative processes to a lesser extent than triiodothyronine.

Venditti P, Chiellini G, Di Stefano L, Napolitano G, Zucchi R, Columbano A, Scanlan TS, Di Meo S.

J Endocrinol. 2010 Jun;205(3):279-89. doi: 10.1677/JOE-10-0036. Epub 2010 Apr 1.

35.

Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine.

Ianculescu AG, Friesema EC, Visser TJ, Giacomini KM, Scanlan TS.

Mol Biosyst. 2010 Aug;6(8):1403-10. doi: 10.1039/b926588k. Epub 2010 Mar 31.

36.

Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice.

Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, Scanlan TS, Miller GM.

J Neurosci Res. 2010 Jul;88(9):1962-9. doi: 10.1002/jnr.22367.

37.

Differential in vivo effects on target pathways of a novel arylpyrazole glucocorticoid receptor modulator compared with prednisolone.

Roohk DJ, Varady KA, Turner SM, Emson CL, Gelling RW, Shankaran M, Lindwall G, Shipp LE, Scanlan TS, Wang JC, Hellerstein MK.

J Pharmacol Exp Ther. 2010 Apr;333(1):281-9. doi: 10.1124/jpet.109.162487. Epub 2010 Jan 11.

38.

Differential effects of TR ligands on hormone dissociation rates: evidence for multiple ligand entry/exit pathways.

Cunha Lima ST, Nguyen NH, Togashi M, Apriletti JW, Nguyen P, Polikarpov I, Scanlan TS, Baxter JD, Webb P.

J Steroid Biochem Mol Biol. 2009 Nov;117(4-5):125-31. doi: 10.1016/j.jsbmb.2009.08.003. Epub 2009 Sep 1.

39.

Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.

Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA.

Cancer Res. 2009 Jul 1;69(13):5415-23. doi: 10.1158/0008-5472.CAN-08-1622. Epub 2009 Jun 23.

40.

Modulation of cardiac ionic homeostasis by 3-iodothyronamine.

Ghelardoni S, Suffredini S, Frascarelli S, Brogioni S, Chiellini G, Ronca-Testoni S, Grandy DK, Scanlan TS, Cerbai E, Zucchi R.

J Cell Mol Med. 2009 Sep;13(9B):3082-90. doi: 10.1111/j.1582-4934.2009.00728.x. Epub 2009 Feb 27.

41.

T3 and the thyroid hormone beta-receptor agonist GC-1 differentially affect metabolic capacity and oxidative damage in rat tissues.

Venditti P, Chiellini G, Bari A, Di Stefano L, Zucchi R, Columbano A, Scanlan TS, Di Meo S.

J Exp Biol. 2009 Apr;212(Pt 7):986-93. doi: 10.1242/jeb.021808.

42.

The thyroid hormone receptor (TR) beta-selective agonist GC-1 inhibits proliferation but induces differentiation and TR beta mRNA expression in mouse and rat osteoblast-like cells.

Beber EH, Capelo LP, Fonseca TL, Costa CC, Lotfi CF, Scanlan TS, Gouveia CH.

Calcif Tissue Int. 2009 Apr;84(4):324-33. doi: 10.1007/s00223-009-9230-1. Epub 2009 Mar 11.

PMID:
19280098
43.

Central effects of thyronamines on glucose metabolism in rats.

Klieverik LP, Foppen E, Ackermans MT, Serlie MJ, Sauerwein HP, Scanlan TS, Grandy DK, Fliers E, Kalsbeek A.

J Endocrinol. 2009 Jun;201(3):377-86. doi: 10.1677/JOE-09-0043. Epub 2009 Mar 9.

44.

The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR(1)).

Tan ES, Naylor JC, Groban ES, Bunzow JR, Jacobson MP, Grandy DK, Scanlan TS.

ACS Chem Biol. 2009 Mar 20;4(3):209-20. doi: 10.1021/cb800304d.

45.

Minireview: 3-Iodothyronamine (T1AM): a new player on the thyroid endocrine team?

Scanlan TS.

Endocrinology. 2009 Mar;150(3):1108-11. doi: 10.1210/en.2008-1596. Epub 2008 Dec 30. Review.

46.

Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo.

Wood WJ, Geraci T, Nilsen A, DeBarber AE, Scanlan TS.

Chembiochem. 2009 Jan 26;10(2):361-5. doi: 10.1002/cbic.200800607.

47.

Identification and characterization of 3-iodothyronamine intracellular transport.

Ianculescu AG, Giacomini KM, Scanlan TS.

Endocrinology. 2009 Apr;150(4):1991-9. doi: 10.1210/en.2008-1339. Epub 2008 Dec 12.

48.

Thyroid hormone receptor subtype specificity for hormone-dependent neurogenesis in Xenopus laevis.

Denver RJ, Hu F, Scanlan TS, Furlow JD.

Dev Biol. 2009 Feb 1;326(1):155-68. doi: 10.1016/j.ydbio.2008.11.005. Epub 2008 Nov 20.

49.

Sobetirome: a case history of bench-to-clinic drug discovery and development.

Scanlan TS.

Heart Fail Rev. 2010 Mar;15(2):177-82. doi: 10.1007/s10741-008-9122-x. Epub 2008 Nov 11. Review.

PMID:
19002578
50.

Complex actions of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines.

Shah V, Nguyen P, Nguyen NH, Togashi M, Scanlan TS, Baxter JD, Webb P.

Mol Cell Endocrinol. 2008 Dec 16;296(1-2):69-77. doi: 10.1016/j.mce.2008.09.016. Epub 2008 Sep 26.

Supplemental Content

Loading ...
Support Center